Manufacturer of Controlled Substances; Notice of Application, 36482 [E7-12947]
Download as PDF
<![CDATA[
36482
Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12941 Filed 7–2–07; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on February 2, 2007, Lipomed, Inc.,
One Broadway, Cambridge,
Massachusetts 02142, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances listed in
schedules II:
Drug
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 13, 2007,
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by letter
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Cocaine (9041) .............................
Ecgonine (9180) ...........................
II
II
jlentini on PROD1PC65 with NOTICES
The company plans on producing
cocaine for sale to its customers, who
are final dosage manufacturers. The
ecgonine is formed during the
manufacturing process for cocaine.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537; or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Federal Register Representative (ODL);
2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12947 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
17:57 Jul 02, 2007
Jkt 211001
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Methaqualone (2565) ...................
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
2,5–Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5–Trimethoxyamphetamine
(7390).
4–Bromo-2,5dimethoxyamphetamine (7391).
4–Bromo-2,5dimethoxyphenethylamine
(7392).
4–Methyl-2,5dimethoxyamphetamine (7395).
2,5–Dimethoxyamphetamine
(7396).
2,5–Dimethoxy-4ethylamphetamine (7399).
3,4–Methylenedioxyamphetamine
(7400).
3,4–Methylenedioxy-Nethylamphetamine (7404).
3,4–
Methylenedioxymethamphetamine (7405).
4–Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Fentanyl (9801) ............................
Sufentanil (9740) ..........................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C 952
(a)(2)(B) may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537; or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
August 2, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C 958(a); 21 U.S.C 823(a); and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
E:\FR\FM\03JYN1.SGM
03JYN1
]]>Agencies
[Federal Register Volume 72, Number 127 (Tuesday, July 3, 2007)]
[Notices]
[Page 36482]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12947]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 13, 2007, Johnson
Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West
Deptford, New Jersey 08066-1742, made application by letter to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cocaine (9041)............................. II
Ecgonine (9180)............................ II
------------------------------------------------------------------------
The company plans on producing cocaine for sale to its customers,
who are final dosage manufacturers. The ecgonine is formed during the
manufacturing process for cocaine.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administrator, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537; or any being sent via
express mail should be sent to Drug Enforcement Administration, Federal
Register Representative (ODL); 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be filed no later than September
4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-12947 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P
